Mandate

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025